Clinical Trial Update: Efficacy and Safety of Etrasimod (APD334) in Inflammatory Bowel Disease Patients With Active Skin Extra-intestinal Manifestations [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating efficacy and safety of etrasimod (APD334) in inflammatory bowel disease with active skin extra-intestinal manifestations has been termi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inflammatory Bowel Disease
• Skin Extra-intestinal Manifestation

Drugs mentioned

• Etrasimod (etrasimod)

Snippet

Sponsor: Arena Pharmaceuticals | Conditions: Inflammatory Bowel Diseases, Skin Extra-intestinal Manifestations | Phase 2 | Status: TERMINATED | Results posted: 2020-12-31